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Clinical neurorestorative therapies recently made great progress for patients with
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spinal cord injury (SCI). This paper systemically reviews historical perspectives, recent
advancements and achievements in SCI through key neurorestorative strategies.
In this study, a search was performed in the PubMed, Scopus, and Scholar Google
search engines using the keywords “neurorestorative strategies”, “spinal cord injury”,
“cell therapy”, “neuromodulation”, and “nerve bridges”. Clinical studies published
in the English language were included. It is paramount for academic community
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involved in this field to take the initiative of a multicenter randomized, double-blind,
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and placebo-control clinical study with high level of evidence-based treatments for
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most SCI neurorestorative strategies in patient management. It is of utmost need to
establish standard therapeutic methods for patients with SCI as early as possible.

Introduction

Currently clinical neurorestorative therapies are able
to help patients with central nervous system (CNS)
diseases or damage for improving their neurological
function and quality of life following complete
chronic spinal cord injury (SCI), stroke, amyotrophic
lateral sclerosis (ALS) and many other diseases [1, 2].
Although, these advancements were made in due
course of time [3, 4]; incorrect viewpoints about

clinical neurorestorative treatment strategies are still
noticed in this area, with special reference to SCI.
This appears to be a common misunderstanding that
“there are no any methods for restoring damaged
neurological structure or functions so far, or even
partial restoration” [5]. These viewpoints fully neglect
excellent contributions and achievements in the field.
On the other hand, the results in SCI are described
as one of the first neurorestorative achievements or
breakthrough [6] using neurorestorative therapies.
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Thus, it is needed to revisit the history, progresses and
achievements of SCI using neurorestorative strategies.
In this review, pioneer trials and major achievement
in several neurorestorative strategies in SCI are
discussed.

2

Methods

A search of the PubMed, Scopus, and Google Scholar
databases for peer-reviewed papers published in the
English language was performed using the keywords
“neurorestorative strategies”, “spinal cord injury”, “cell
therapy”, “neuromodulation”, and “nerve bridges”
between 1967 and 2018, all of which display the
historical events, and recent main advancements and
achievements in SCI treatment.
Review articles and/or non-original papers were
excluded, along with duplicate publications of the
same original study and letters to the editor. Original
papers reporting a definitive intervention in a stated
number of patients were included in the analysis. In
the case of two or three publications emanating from
one study, the version with the longest follow-up
and/or fullest reporting was included. All the included
studies had been approved by local institutional
review boards.

3

Disscussion

Neurorestorative strategies in SCI include pharmacotherapy, surgical procedures (such as intramedullary
decompression and nerve bridges), neural tissue or cell
transplantation, neurostimulation, neuromodulation,
brain machine interface (BMI), tissue engineering,
bioengineering, intensive neurorehabilitation, omental
transposition, and other combined modalities.
3.1

Pharmacotherapy

Neurorestorative pharmacotherapy is used to prevent
secondary neural damage through neuroprotection.
This modality would attenuate cellular apoptosis or
necrosis leading to neuronal and axonal survival.
3.1.1 Methylprednisolone (MP)
Bracken et al. (1990) reported that high-dose of
methylprednisolone (MP) administration is an effective
therapy in SCI during acute phase. The national acute

spinal cord injury studies (NASCIS) II and III, have
shown improvement in motor function and sensation
in patients with complete or incomplete SCI. This
was once considered the first effective strategy of
neurological restoration at an early stage of SCI [7–9].
However, soon it became controversial because of
enough evidence of serious complications compared
to benefits. These complications included infection,
respiratory impairment, gastrointestinal bleeding,
and even death. High-dose MP therapy is no longer
used routinely in acute SCI, but remains an optional
therapeutic approach in certain conditions [10–15].
The current recommendation is to treat all patients
with SCI according to local or regional protocol if
steroids are recommended.
3.1.2 Ganglioside (GM-1)
Geisler (1991) reported that GM-1 enhanced the
recovery of neurologic function in SCI after one year
of follow-up [16]. However, in 2001, a multicenter
randomized, double-blind, and placebo-control clinical
trial did not show significant differences between
treatment group and control cases [17]. Thus, GM-1
is not recommended as a routine therapy in acute SCI
[12, 18–20].
3.1.3

Other pharmacotherapeutic trials

Neither naloxone nor tirilazad mesylate therapy
showed therapeutic benefits in patients with SCI in
clinical trials [21]. Administration of human erythropoietin did not improve the functional outcome
of patients with traumatic injuries to cervical spinal
cord [22]. Although minocycline (Casha) showed a
tendency towards improvement in several functional
parameters in SCI, it failed to show restoring efficacy
in SCI [23]. Acidic fibroblast growth factor (aFGF) [24]
and granulocyte-colony stimulating factor (GCSF) have
shown some benefits in cases of incomplete SCI [25],
but more evidences and further studies are required.
Neurorestorative pharmacotherapy managment in
SCI is still a long way to achieve progress in SCI treatment. It is worth mentioning that a small progress of
restoring neurological functions by pharmacotherapy
should be valued and explored further.
3.2

Neurorestorative surgery

There are two kinds of neurorestorative surgery for
Journal of Neurorestoratology
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SCI namely intramedullary decompression and nerve
bridges.
3.2.1 Intramedullary decompression or myelotomy
Galanda (1974) and Yamada (1976) reported that
myelotomy could help patients with spasticity or
spasms in chronic SCI to improve their walking
ability [26, 27]. Whereas, Borovich (1978) reported
that myelotomy didn’t improve patients’ neurological
functions in acute cervical cord injury [28]. Wu (1981)
suggested that necrotic tissue should be washed out
by saline or gently sucked in acute SCI [29] for better
results. Tachibana (1984) and Koyanagi (1989) reported
that myelotomy was effective in preventing secondary
neurological damages in SCI [30, 31]. So far it remains
controversial whether myelotomy or removing necrotic tissue in the central gray matter can be effective
to prevent secondary damage in SCI and restore
patients’ neurological functions. Therefore, multicenter,
randomized, double-blind, placebo-controlled clinical
studies should be done to confirm evidence of
neurorestorative effects.
3.2.2

Nerve bridges

Carlsson (1967) was the first to report that reconstructing efferent pathways to the urinary bladder for
a paraplegic child resulted in urine control improvement [32]. Twenty years later, more experts started to
perform similar surgical procedures for SCI, and
showed partial neurological functional improvements
[33–36]. Due to the nature of the invasive procedures,
it is difficult to perform control clinical studies, hence
nerve bridges are not routinely used methods in SCI.
Larger randomized clinical studies are necessary to
make this procedure a standardized treatment method
for SCI.
3.3 Neural tissue or cell transplantation
3.3.1

Neural tissue transplantation

Iumashev (1989) reported that peripheral nerve transplant in SCI resulted in improvement of sensation
and movement [37]. He (1995) transplanted fetal
brain tissue and Falci (1997) transplanted embryonic
spinal cord grafts in SCI for functional improvements
[38, 39]. Afterward there were few reports of fetal or
embryonic tissue transplantation in SCI.
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3.3.2

Cell transplantation

Huang (2003) and Rabinovich (2003) reported that
olfactory ensheathing cell (OEC) transplantation
could restore some neurological functions for chronic
SCI [40, 41]. Later on several other kinds of cells, such
as bone marrow, mononuclear cell (BMMC), mesenchymal stromal cells (MSC) and etc., were used for
SCI therapy through different transplanting ways and
various kinds of other cells were used as combined
therapy to treat SCI patients [42–47]. The majority of
those cell therapy reports could help patients with
SCI in recovering partial lost functions and improve
their quality of life. But all these cell therapies did not
become a routine treatment for SCI. The reason for
no advancement in this area is the lack of clinical cell
therapy trials in SCI through multicenter, randomized,
double-blind placebo-control studies. Thus, the clinical
trials of high level of evidence-based medical evidence
is the key issue in this field.
3.4

3.4.1

Neurostimulation or neuromodulation and brain
machine interface
Neurostimulation or neuromodulation

von Wild (2002) reported that computer added locomotion by implanted electrical stimulation in paraplegic
patients showed some functional recovery [48].
Minassian (2004) found that stepping-like movements
could be induced by epidural stimulation in humans
with complete SCI [49] as shown in similar studies
later [50–53]. Recently, more reports using this method
showed positive results in patients with complete
chronic SCI by partially restoring their standing and
walking abilities [54, 55]
3.4.2

Brain machine interface

Simeral (2011) reported that implanting an intracortical microelectrode array could help a tetraplegic
patient in neural control of cursor trajectory and
click [56]. Hochberg (2012) showed that patients with
tetraplegia using a neurally controlled robotic arm
initiate function and grasp [57]. Onose (2012) reported
that using motor imagery EEG-based brain-computer
interface (BCI) could help chronic tetraplegics to do
robotic arm control [58]. Collinger (2012) showed that
a patient with tetraplegia is able to guide a robotic
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arm with thoughts through high-performance neuroprosthetic control [59]. Mignardot (2017) reported that
the multidirectional gravity-assist enabled natural
walking in non-ambulatory individuals with SCI and
enhanced skilled locomotor control [60].
3.5

Tissue engineering

Bryukhovetskiy（2015）reported that biodegradable
polymers SpheroGel used to fill into a cavity of spinal
cord for patients with SCI helped them in improving
some of their neurological functions [61]. Zhao et al.
reported NeuroRegen scaffold with human umbilical
cord blood‐mesenchymal stromal cells was effective
in improving neurological functions for patients with
chronic SCI [62]. This tissue engineering therapy did
not fully clarify whether injured spinal tissue should be
totally resected two months after injury and whether
the procedure “totally resecting injured spinal cord
tissue” is beneficial or harmful for SCI patients. It is
known that patients with complete SCI have a potential
to restore some neurological functions spontaneously
or through neurorestorative therapies several years
late [1, 2]. Tissue engineering should have a clear
indication and contraindication for patients with
complete SCI. Total excision of injured spinal cord
must be carefully managed.
3.6

Bioengineering

functional recovery [67]. Following his study, some
researchers reported similar results. However, this
method did not show any further progress in the last
ten years.
3.9

Other methods

3.9.1

Sural nerve graft

Cheng (2004) reported that sural nerve graft bridged
and reconnected specific pathways of spinal cord from
white to gray matter helped the patient recover some
functions [68]. On the other hand Barros (2004) did not
achieve similar results using the same method [69].
3.9.2

Hypothermic treatment

Negrin J (1973) showed that hypothermia was helpful
for acute and chronic post-traumatic paraplegic
patient [70]; yet this method is not employed to treat
patients with SCI.
3.9.3 Acupuncture for spinal cord injury
Gao (1996) and Cheng (1998) reported that acupuncture treatment was helpful in complete SCI [71, 72].
Even though this therapy showed some help in SCI,
it needs further evidence based evaluation.
3.10 Combined therapies
3.10.1 Different cell combination

Kucher (2018) reported that human anti-Nogo-A
antibody was well tolerated in patients with acute
complete SCI through intrathecal administration and
showed some efficacy [63]. This antibody therapy still
needs multicenter, randomized, double-blind placebocontrolled clinical trials.

Rabinovich (2003), Moviglia (2006) and Seledtsova
(2010) reported that transplantation of OEC or/and
BMMC combination in patients with SCI, showed
some functional recovery [41, 73, 74].

3.7

Moviglia (2006) reported that combined protocol of
cell therapy for chronic SCI by intravenous (IV) and
intra-arterial (IA) showed electrical and functional
recovery [46]. Geffner(2008) reported that autologous
BMMCs via multiple routes was safe for patients
with SCI and improve their quality of life [75].

Intense neurorehabilitation

McDonald (2002) reported that a patient with complete chronic SCI recovered from ASIA_A to ASIA-C
through intense neurorehabilitation [64]. Later, more
similar reports were published [65, 66]. Unfortunately,
there are no multicenter, randomized, double-blind
placebo-control trials for this method yet.
3.8

Omental transposition

Goldsmith (1986) reported that omental transposition
treating patients with chronic SCI showed some

3.10.2 Multiple routes of cell administration

3.10.3

Combined cell therapy and Laserponcture

Bohbot (2010) reported that olfactory ensheathing glia
transplantation combined with LASERPONCTURE
in human SCI showed improvement as measured by
electromyography monitoring [76].
Journal of Neurorestoratology
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3.10.4 Cell therapy combination with neurorehabilitation
Huang (2012) reported that patients with chronic complete SCI following OEC transplantation in combination
with intensive neurorehabilitation exercises showed
better outcome compared to patients with minimal
neurorehabilitation exercise [47].

4

Summary

It is very hard to make any progress in restoring
neurological functions for SCI patients, particularly
for chronic complete SCI; hence any scientific work
or progress in this field should be highly welcomed.
Currently these individuals with chronic complete
SCI have chances to partially restore their neurological structure and functions through cell therapy,
neuromodulation/neurostimulation, nerve bridges,
intensive rehabilitation exercise and other related
procedures [2]. It is likely that future neurorestorative
therapies can result in a big breakthrough for patients
suffering from chronic complete SCI and restore more
functions. Researchers in the field of Neurorestoratology
should respect pioneers’ contribution and achievements in relation to their own work. The future of
neurorestoratology relies on multicenter, randomized,
double-blind, and placebo-control clinical studies to
obtain higher level of evidence-based results. This
would allow most SCI neurorestorative strategies to
become standard treatment methods for patients
with SCI.
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